Pushkal Garg sold $1.3M of ALNY
EVP Chief R&D at ALNYLAM PHARMACEUTICALS, INC.. 2,851 shares at an average of $455.89, traded Aug 18, 2025, filed Aug 19, 2025.
Score components
- +15RoleOfficer
- +25Trade size$1.3M at market
- +5Share of holdings soldSold 12% of holdings
- +15Cluster7 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001735276-25-000092, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 15, 2025 | AGrant or award Common Stock10b5-1 | +2,851 | $0.00 | $0 | 23,072 | Aug 19, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock10b5-1 | -39 | $447.98 | $17k | 23,033 | Aug 19, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock10b5-1 | -90 | $449.92 | $40k | 22,943 | Aug 19, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock10b5-1 | -39 | $450.92 | $18k | 22,904 | Aug 19, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock10b5-1 | -103 | $451.99 | $47k | 22,801 | Aug 19, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock10b5-1 | -329 | $452.96 | $149k | 22,472 | Aug 19, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock10b5-1 | -543 | $454.04 | $247k | 21,929 | Aug 19, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock10b5-1 | -241 | $454.84 | $110k | 21,688 | Aug 19, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock10b5-1 | -12 | $455.82 | $5,470 | 21,676 | Aug 19, 2025 |
| Aug 19, 2025 | SOpen-market sale Common Stock10b5-1 | -276 | $455.41 | $126k | 21,400 | Aug 19, 2025 |
| Aug 19, 2025 | SOpen-market sale Common Stock10b5-1 | -338 | $457.26 | $155k | 21,062 | Aug 19, 2025 |
| Aug 19, 2025 | SOpen-market sale Common Stock10b5-1 | -231 | $458.27 | $106k | 20,831 | Aug 19, 2025 |
| Aug 19, 2025 | SOpen-market sale Common Stock10b5-1 | -260 | $459.59 | $119k | 20,571 | Aug 19, 2025 |
| Aug 19, 2025 | SOpen-market sale Common Stock10b5-1 | -305 | $461.01 | $141k | 20,266 | Aug 19, 2025 |
| Aug 19, 2025 | SOpen-market sale Common Stock10b5-1 | -45 | $461.74 | $21k | 20,221 | Aug 19, 2025 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 23Weak | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $5.5M 12,128 shares | -36% | |
| 33Weak | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $12M 25,650 shares | -32% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $2.7M 5,959 shares | -23% | |
| 55Moderate | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $1.1M 2,441 shares | -9% | |
| 50Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $635k 1,405 shares | -5% | |
| 70Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $4.0M 8,924 shares | -12% | |
| 62Notable | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $1.7M 3,821 shares | -7% | |
| 33Weak | ALNYLAM PHARMACEUTICALS, INC. | Colleen F Reitan director | $8.4M 18,000 shares | -96% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $1.6M 3,474 shares | -12% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.